Publicaciones en colaboración con investigadores/as de Hospital Universitario La Paz (115)

2024

  1. Practical use of new therapies for the management of dyslipidaemias. Consensus SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N.

    REC: CardioClinics

2023

  1. Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

    Clinical and Translational Oncology, Vol. 25, Núm. 11, pp. 3073-3085

  2. Current situation of the comprehensive approach of heart failure in Spain. The OPTIMISE-IC project

    REC: CardioClinics, Vol. 58, Núm. 4, pp. 289-302

  3. Impact of the Spanish consensus for improving lipid control on patients admitted for an acute coronary syndrome

    Journal of Clinical Lipidology, Vol. 17, Núm. 6, pp. 756-764

  4. Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study

    Medicina (Lithuania), Vol. 59, Núm. 10

  5. Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study

    Journal of Clinical Medicine, Vol. 12, Núm. 9

  6. SGLT 2 inhibitors: Searching for the best in class

    International Journal of Cardiology

  7. Selection of the best of 2022 in clinical cardiology and cardiovascular pharmacotherapy

    REC: CardioClinics, Vol. 58, pp. S49-S54

  8. Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]

    Endocrinologia, Diabetes y Nutricion, Vol. 70, pp. 51-62

2022

  1. Chronic coronary syndrome: practical management of antianginal drugs.

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SE, pp. 1-10

  2. Comprehensive management of risk factors in peripheral vascular disease. Expert consensus

    Revista Clinica Espanola, Vol. 222, Núm. 2, pp. 82-90

  3. Correction to: Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non‑Asian Patients with Atrial Fibrillation: A Systematic Review and Meta‑Analysis (Clinical Drug Investigation, (2021), 41, 11, (941-953), 10.1007/s40261-021-01091-w)

    Clinical Drug Investigation

  4. Evaluation of prophylaxis in primary prevention with acetylsalicylic acid in people with diabetes: A scoping review

    Semergen, Vol. 48, Núm. 4, pp. 275-292

  5. Knowledge of the clinical cardiologist on high-risk type 2 diabetes mellitus. What do we know and how can we improve?

    REC: CardioClinics, Vol. 57, Núm. 4, pp. 263-270

  6. Prognostic value of a model based on IC-BERG recommendations in ambulatory patients with heart failure

    REC: CardioClinics, Vol. 57, Núm. 2, pp. 76-84

  7. SEMERGEN positioning on approaching chronic heart failure in primary care

    Semergen, Vol. 48, Núm. 2, pp. 106-123

  8. Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study

    Frontiers in Cardiovascular Medicine, Vol. 9

  9. Which patients could benefit from the use of bempedoic acid in clinical practice?

    Revista Espanola de Cardiologia, Vol. 75, Núm. 10, pp. 848-849

2021

  1. A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: The DAFNE score

    Future Cardiology, Vol. 17, Núm. 4, pp. 685-692

  2. Analysis of the prescription process of PCSK9 inhibitors in the cardiology departments of Spanish hospitals and optimization proposal. The IKIGAI study

    Clinica e Investigacion en Arteriosclerosis, Vol. 33, Núm. 6, pp. 296-305